---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-053836"
form_type: "8-K"
ticker: "DTIL"
cik: "0001357874"
company_name: "PRECISION BIOSCIENCES INC"
filed_at: "2026-08-06T11:16:15+00:00"
generated_at: "2026-08-06T11:20:11.049382+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Precision BioSciences reports first clinical evidence of cccDNA elimination in HBV; Q2 net loss $32.7M

## Summary
- Liver biopsy showed 1-log reduction in cccDNA with <1% remaining after two PBGENE-HBV doses.
- pgRNA became undetectable in 100% of evaluable patients; sustained up to six months.
- Cash balance $112.4M as of June 30, 2026; expected to fund milestones through 2028.
- Net loss $32.7M ($1.26/share) vs $23.5M ($2.13/share) in Q2 2025; non-cash warrant loss drove increase.
- Alex Kelly promoted to COO; Naresh Tanna promoted to CFO; Cassie Gorsuch now leads all research.

## SEC filing metadata
- accession: 0001628280-26-053836
- form_type: 8-K
- ticker: DTIL
- cik: 0001357874
- company_name: PRECISION BIOSCIENCES INC
- filed_at: 2026-08-06T11:16:15+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1357874/000162828026053836/0001628280-26-053836-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1357874/000162828026053836/dtil-20260806.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-053836
- JSON: https://secwatch.observer/filing/0001628280-26-053836.json
- Plain text: https://secwatch.observer/filing/0001628280-26-053836.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.